🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

277 results for “combination” Clear

  1. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  2. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  3. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  4. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  5. Vaccine/device combination for prevention of HFRS

    United Therapeutics Europe Ltd

    Hemorrhagic Fever With Renal Syndrome

    phase 1 mab completed

    1 trial

  6. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  7. WX-UK1 in combination with Capecitabine

    United Therapeutics Europe Ltd

    Advanced Malignancies

    phase 1 small molecule completed

    1 trial

  8. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

    phase 1 small molecule completed

    1 trial

  9. ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  10. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  11. Amlodipine besylate/atorvastatin calcium single pill combination

    Pfizer

    Hypertension

    approved small molecule completed

    1 trial

  12. Artemether-lumefantrine combination

    United Therapeutics Europe Ltd

    Plasmodium Vivax Infection

    approved small molecule completed

    1 trial

  13. Artesunate-amodiaquine combination

    United Therapeutics Europe Ltd

    Malaria,Falciparum

    approved small molecule completed

    1 trial

  14. COMBINATIONS

    Disc Medicine

    muscle protein turnover hemodialysis

    approved small molecule active

    1 trial

  15. Coartem™ (Artemether-lumefantrine combination)

    United Therapeutics Europe Ltd

    Malaria

    approved small molecule completed

    1 trial

  16. Combination Cinacalcet with Vitamin D analogue

    Hospital Authority, Hong Kong

    Secondary Hyperparathyroidism

    approved small molecule active

    1 trial

  17. Combination NRT (Nicotine patch, Nicotine lozenge)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule completed

    1 trial

  18. Combination of antiplatelet drugs and anticoagulants for at least one month

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial

  19. Dexmedetomidine-esketamine combination

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule active

    1 trial

  20. Glycopyrronium in Combination With Tropisetron

    The First People's Hospital of Lianyungang

    Postoperative Nausea and Vomiting

    approved small molecule completed

    1 trial

  21. Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    approved small molecule completed

    1 trial

  22. Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)

    Takeda

    Prothrombin Complex Factor Deficiency

    approved mab completed

    1 trial

  23. Triple combination therapy group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  24. brinzolamide 1%/brimonidine 0.2% fixed combination

    Novartis Pharmaceuticals

    Glaucoma

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources